A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)
Chronic obstructive pulmonary disease (COPD)
40 Years - 130 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Dec 2023 by AstraZeneca
No locations available
|Experimental: Tozorakimab Dose 1|
Dosing subcutaneously tozorakimab Dose 1 and placebo
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
|Experimental: Tozorakimab Dose 2|
Dosing subcutaneously tozorakimab Dose 2
Administered subcutaneously tozorakimab Dose 2 through Week 52.
|Placebo Comparator: Placebo|
Dosing subcutaneously with equivalent volume to tozorakimab
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.